» Articles » PMID: 24685624

Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2014 Apr 2
PMID 24685624
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Impairment in instrumental activities of daily living (IADL) heralds the transition from mild cognitive impairment (MCI) to dementia and is a major source of burden for both the patient and caregiver.

Objective: To investigate the relationship between IADL and regional cortical thinning and cerebrospinal fluid (CSF) Alzheimer's disease (AD) biomarkers cross-sectionally and longitudinally in clinically normal (CN) elderly, MCI, and mild AD dementia subjects.

Methods: Two hundred and twenty nine CN, 395 MCI, and 188 AD dementia subjects participating in the Alzheimer's Disease Neuroimaging Initiative underwent baseline magnetic resonance imaging, baseline lumbar puncture, and clinical assessments, including the Functional Activities Questionnaire used to measure IADL, every 6 to 12 months up to 3 years. General linear regression and mixed effects models were employed.

Results: IADL impairment was associated with the interactions between lower inferior temporal cortical thickness and diagnosis (p < 0.0001), greater lateral occipital cortical thickness and diagnosis (p < 0.0001), and greater amyloid-β 1-42 (Aβ1-42) and diagnosis (p = 0.0002) at baseline (driven by AD dementia). Lower baseline supramarginal (p = 0.02) and inferior temporal (p = 0.05) cortical thickness, lower Aβ1-42 (p < 0.0001), and greater total tau (t-tau) (p = 0.02) were associated with greater rate of IADL impairment over time.

Conclusions: Temporal atrophy is associated with IADL impairment in mild AD dementia at baseline, while baseline parietal and temporal atrophy, lower CSF Aβ1-42, and greater t-tau predict worsening IADL impairment over time across the AD spectrum. These results emphasize the importance of assessing IADL at the stage of MCI and even at the transition from CN to MCI.

Citing Articles

Genetic polymorphism in β-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in Alzheimer's disease: an exploratory study.

Yin W, Li Z, Zheng W, Zhou X, Wan K, Tang Y Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 39733191 DOI: 10.1007/s00406-024-01953-2.


Longitudinal Evolution of Financial Capacity and Cerebral Tau and Amyloid Burden in Older Adults with Normal Cognition or Mild Cognitive Impairment.

Mimmack K, Sprague E, Amariglio R, Vannini P, Marshall G J Prev Alzheimers Dis. 2024; 11(4):966-974.

PMID: 39044507 PMC: 11269767. DOI: 10.14283/jpad.2023.121.


Regional cerebral tau predicts decline in everyday functioning across the Alzheimer's disease spectrum.

Dubbelman M, Mimmack K, Sprague E, Amariglio R, Vannini P, Marshall G Alzheimers Res Ther. 2023; 15(1):120.

PMID: 37408004 PMC: 10320884. DOI: 10.1186/s13195-023-01267-w.


Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.

Gonzalez C, Mimmack K, Amariglio R, Becker J, Chhatwal J, Fitzpatrick C J Alzheimers Dis. 2023; 94(1):217-226.

PMID: 37212093 PMC: 10330453. DOI: 10.3233/JAD-220885.


Brain health registry updates: An online longitudinal neuroscience platform.

Weiner M, Aaronson A, Eichenbaum J, Kwang W, Ashford M, Gummadi S Alzheimers Dement. 2023; 19(11):4935-4951.

PMID: 36965096 PMC: 10518371. DOI: 10.1002/alz.13077.


References
1.
Salmon E, Lespagnard S, Marique P, Peeters F, Herholz K, Perani D . Cerebral metabolic correlates of four dementia scales in Alzheimer's disease. J Neurol. 2005; 252(3):283-90. DOI: 10.1007/s00415-005-0551-3. View

2.
Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2004; 51(2):336-45. DOI: 10.1373/clinchem.2004.039347. View

3.
Shaw L, Vanderstichele H, Knapik-Czajka M, Clark C, Aisen P, Petersen R . Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009; 65(4):403-13. PMC: 2696350. DOI: 10.1002/ana.21610. View

4.
Tabert M, Albert S, Camacho Y, Pelton G, Liu X, Stern Y . Functional deficits in patients with mild cognitive impairment: prediction of AD. Neurology. 2002; 58(5):758-64. DOI: 10.1212/wnl.58.5.758. View

5.
Okonkwo O, Alosco M, Jerskey B, Sweet L, Ott B, Tremont G . Cerebral atrophy, apolipoprotein E varepsilon4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. Alzheimers Dement. 2010; 6(5):404-11. PMC: 2950092. DOI: 10.1016/j.jalz.2010.02.003. View